정관 수술 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 환자별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Global Vasectomy Market was valued at USD 22.75 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.60% through 2030. The global vasectomy market refers to the industry involved in the provision of vasectomy services and related products. Vasectomy is a surgical procedure used for permanent male contraception, where the vas deferens, the tubes that carry sperm from the testicles, are cut or sealed.

Key Market Drivers

Rising Awareness About Male Contraception and Family Planning

The increasing awareness of male contraception and family planning is one of the most significant drivers of the global vasectomy market. Globally, 966 million women of reproductive age are utilizing some form of contraception. Among the 1.9 billion women aged 15 to 49, approximately 874 million rely on modern contraceptive methods, while 92 million use traditional methods. These figures highlight the substantial market penetration of modern contraceptive solutions and the continued demand for both contemporary and conventional birth control options. This shift is fueled by government initiatives, changing societal norms, education programs, and advocacy efforts, all of which contribute to a higher adoption rate of vasectomy as a preferred method of permanent birth control. Governments, international organizations (such as WHO and UNFPA), and NGOs actively promote vasectomy as a safe, effective, and low-cost family planning solution. In many countries, free or heavily subsidized vasectomy procedures are offered as part of public healthcare programs, increasing accessibility for lower-income populations. Some governments provide financial incentives or additional healthcare benefits to men opting for vasectomy, driving adoption rates.

Traditionally, contraception has been considered a woman's responsibility. However, modern awareness programs emphasize that men should also take an active role in birth control. As societies progress toward gender equality, more men are willing to undergo vasectomy to share the responsibility of family planning, reducing the burden on women. As more men become proactive in reproductive health decisions, demand for vasectomy procedures rises, particularly in urban and educated populations. More healthcare professionals, urologists, and family planning counselors are recommending vasectomy as a safe and effective alternative to female sterilization. Historically, misconceptions about vasectomy (such as loss of sexual function or masculinity) have deterred men from opting for the procedure. Educational initiatives are correcting these myths, leading to increased confidence in the procedure. A better-informed population results in greater acceptance of vasectomy, increasing patient willingness to undergo the procedure and expanding the market. Companies and local organizations are integrating vasectomy awareness into employee wellness programs and community healthcare initiatives. The expansion of digital health platforms, social media, and online healthcare providers makes educational content about vasectomy more widely available. This drives higher procedural uptake as men gain easier access to reliable information and healthcare services.

Key Market Challenges

Cultural Stigma and Misconceptions

One of the foremost challenges in the global vasectomy market is the persistence of cultural stigma and misconceptions surrounding the procedure. In some societies, vasectomy is still associated with emasculation or concerns about sexual performance. Misunderstandings about the procedure's reversibility or its impact on masculinity deter potential candidates. Addressing these misconceptions through education and awareness campaigns is crucial to overcoming this challenge.

Key Market Trends

Minimally Invasive Techniques

While minimally invasive techniques, such as non-scalpel vasectomy, have already gained traction, ongoing research and innovation are expected to further refine these approaches. Continued improvements in surgical techniques will lead to even shorter recovery times, reduced discomfort, and fewer complications, making vasectomy an even more attractive choice for potential candidates.

Key Market Players

• Pfizer Inc
• Bristol Myers Squibb SA
• Teva Pharmaceuticals USA Inc
• Upsher-Smith Laboratories Inc
• SMITHFIELD BIOSCIENCE
• Opocrin SPA
• Bioiberica SA
• GSK PLC
• Johnson & Johnson Consumer Inc
• Fresenius SE & Co KGaA

Report Scope:

In this report, the Global Vasectomy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vasectomy Market, By Type:

• Conventional
• Minimally Invasive
• No-Scalpel

Vasectomy Market, By Patient:

• Animal
• Human

Vasectomy Market, By End-User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Vasectomy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vasectomy Market.

Available Customizations:

Global Vasectomy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Vasectomy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Conventional, Minimally Invasive, No-Scalpel)
  • 5.2.2. By Patient (Animal, Human)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Type
  • 5.3.2. By Patient
  • 5.3.3. By End-User
  • 5.3.4. By Region

6. North America Vasectomy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Conventional, Minimally Invasive, No-Scalpel)
  • 6.2.2. By Patient (Animal, Human)
  • 6.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Vasectomy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Patient
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Vasectomy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Patient
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Vasectomy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Patient
      • 6.3.3.2.3. By End-User

7. Europe Vasectomy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Conventional, Minimally Invasive, No-Scalpel)
  • 7.2.2. By Patient (Animal, Human)
  • 7.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Vasectomy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Patient
      • 7.3.1.2.3. By End-User
  • 7.3.2. United Kingdom Vasectomy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Patient
      • 7.3.2.2.3. By End-User
  • 7.3.3. France Vasectomy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Patient
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Vasectomy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Patient
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Vasectomy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Patient
      • 7.3.5.2.3. By End-User

8. Asia-Pacific Vasectomy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Conventional, Minimally Invasive, No-Scalpel)
  • 8.2.2. By Patient (Animal, Human)
  • 8.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Vasectomy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Patient
      • 8.3.1.2.3. By End-User
  • 8.3.2. Japan Vasectomy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Patient
      • 8.3.2.2.3. By End-User
  • 8.3.3. India Vasectomy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Patient
      • 8.3.3.2.3. By End-User
  • 8.3.4. Australia Vasectomy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Patient
      • 8.3.4.2.3. By End-User
  • 8.3.5. South Korea Vasectomy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Patient
      • 8.3.5.2.3. By End-User

9. South America Vasectomy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Conventional, Minimally Invasive, No-Scalpel)
  • 9.2.2. By Patient (Animal, Human)
  • 9.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Vasectomy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Patient
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Vasectomy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Patient
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Vasectomy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Patient
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Vasectomy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Conventional, Minimally Invasive, No-Scalpel)
  • 10.2.2. By Patient (Animal, Human)
  • 10.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Vasectomy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Patient
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Vasectomy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Patient
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Vasectomy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Patient
      • 10.3.3.2.3. By End-User
  • 10.3.4. Kuwait Vasectomy Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By Patient
      • 10.3.4.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Pfizer Inc
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Bristol Myers Squibb SA
• 14.3. Teva Pharmaceuticals USA Inc
• 14.4. Upsher-Smith Laboratories Inc
• 14.5. SMITHFIELD BIOSCIENCE
• 14.6. Opocrin SPA
• 14.7. Bioiberica SA
• 14.8. GSK PLC
• 14.9. Johnson & Johnson Consumer Inc
• 14.10. Fresenius SE & Co KGaA

15. Strategic Recommendations

16. About Us & Disclaimer